Understanding brain function in individuals with Down syndrome
Noradrenergic dysfunction in Down Syndrome
This study is looking at how problems with certain brain cells might affect memory and increase the risk of Alzheimer's in people with Down syndrome, and it hopes to find new ways to help improve thinking skills using existing medications.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10615297 on NIH RePORTER |
What this research studies
This research investigates the role of noradrenergic dysfunction in individuals with Down syndrome (DS) and its potential link to Alzheimer's disease (AD). The study aims to explore how early degeneration of noradrenergic neurons may contribute to memory impairment and AD pathology in DS. By examining the effects of noradrenergic signaling and its impact on brain health, the research seeks to identify new therapeutic approaches that could protect cognitive function in this population. Patients may benefit from insights into how existing medications that enhance noradrenergic activity could be used to improve their cognitive health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with Down syndrome, particularly those who may be at risk for developing Alzheimer's disease.
Not a fit: Patients without Down syndrome or those who do not exhibit cognitive impairment related to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that help preserve cognitive function in individuals with Down syndrome as they age.
How similar studies have performed: Previous research has shown promising results in understanding the role of noradrenergic systems in cognitive decline, suggesting that this approach may yield valuable insights.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Ledreux, Aurélie — University of Colorado Denver
- Study coordinator: Ledreux, Aurélie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.